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Abstract
Introduction: Chronic lower back pain is a leading cause of disability in US adults. Opioid use continues to
be controversial despite the Centers for Disease Control and Prevention guidance on chronic pain
management to use nonpharmacologic and nonopioid pharmacologic interventions. The objectives of the
study were to assess the impact of early physical therapy (PT) intervention on improving functionality and
reducing opioid burden in patients with chronic lower back pain.
Methods: A single-center, retrospective chart review of patients receiving 6 PT visits and treated with
either opioids first (OF) or PT first (PTF) therapy for chronic lower back pain were evaluated. Concomitant
use of nonopioid and nonpharmacologic therapy was permitted. The Oswestry Disability Index (ODI), a
survey measuring functionality, was recorded for PTF group. Pain scores and medication use including
opioids were collected at treatment initiation and completion.
Results: One hundred and eighty patients were included in three groups: OF group (n¼60), PTF group
(n¼60), and PTFþODI group (n¼60). The PTFþODI group had mean ODI reduction of 11.9% (P , .001).
More OF patients were lost to follow up (68.3%) or failed PT (60%) compared to the PTF group, 38.3% and
3.3% (P , .001). Reduction in both opioid and nonopioid medications as well as pain scores were observed
but not statistically significant.
Discussion: Early PT resulted in improved functionality, decreased pain, and reduced medication use upon
PT completion. These findings suggest PT, along with nonopioid modalities, are a viable first-line option for
the management of chronic lower back pain.
Keywords: physical therapy, chronic lower back pain, lower back pain, pain, opioids, Oswestry Disability
Index
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Introduction
About 10% to 20% of individuals with acute lower back
pain will develop chronic lower back pain (CLBP). Chronic
lower back pain was defined using National Institute of
Neurological Disorders and Stroke1 definition of pain and
disability persisting for more than 3 months. In the United
States, CLBP is the third leading disease contributing to
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disability adjusted life years with a mean increase of 24%
from 1990 to 2010.1-4 Lost work days from CLBP is
approximately 149 million days per year accruing costs
upwards of $100 billion to $200 billion annually.5 Chronic
lower back pain is often managed by opioids but use as
first-line therapy remains controversial. Not only are
opioids associated with tolerance and risk of addiction,
patients with CLBP have reduced progress in regaining
functionality.6 Kidner et al6 found the work-return rate for
very high opioid users (.120 mg/d of morphine equiva-
lents) versus nonopioid users was 76% and 94%,
respectively. Compared to other specialties, family
practice, general practice, and internal medicine opioid
prescription use per capita increased by 7.35% between
2007 to 2012.5,7 Despite recent improved prescribing
habits, the repercussions in disability and patient harm are
still evident as patients continue to struggle with
addiction, substance use, chronic pain, and psychiatric
comorbidities.8-10
In 2016, the Centers for Disease Control and Prevention
(CDC)5 published guidelines to improve opioid prescribing
habits and reduce opioid harm in individuals using opioids
chronically. The CDC recommends using pharmacologic
and nonpharmacologic strategies. The guidelines5 encour-
age caution when prescribing opioids by using the lowest
effective dose, using immediate release formulations,
developing treatment goals, and discussing risks as well as
benefits with the patient. Furthermore, CLBP studies have
shown exercise reduces pain and improves functionality
but no specific type of exercise or therapy were
recommended.11-16 Lastly, Gomes et al8 and Dunn et al9
showed opioid use for chronic pain was associated with
increased overdose rates in patients using higher doses. A
2.5-fold higher risk of overdose (hazard ratio 2.33,
confidence interval [CI] 1.26-4.32) was found when long-
acting opioids were used compared to the immediate-
release formulations.10 With significant dangers associat-
ed with opioid use, additional studies in CLBP to evaluate
the benefit of specific nonpharmacologic interventions
such as physical therapy (PT) and impact on medication
use for pain management are needed. Benefits of
improved functionality and decreased opioid use may
theoretically provide improved outcomes in treatment of
neurologic and psychiatric comorbidities. This study’s
objective was to assess the impact of early PT interven-
tion on improving functionality and opioid burden
reduction in patients with CLBP.
Methods
This study, approved by the Scripps Institutional Review
Board, was a single-institution, retrospective chart review
conducted at Family Health Centers of San Diego
(FHCSD), Department of Physical Therapy in collaboration
with Scripps Mercy Hospital San Diego, Department of
Pharmacy using FHCSD electronic health records between
January 1, 2014 and August 14, 2018. This study was
originally designed to evaluate reduction in opioid burden
with early PT confirmed by temporal relationship when
opiate(s) were used prior or after PT initiation. The opioids
first (OF) group was identified by patients using opioids
prior to PT initiation, and the PT first (PTF) group, referred
to as early PT, were patients not using opioids at PT
initiation. When the Oswestry Disability Index (ODI)
survey for monitoring functional improvement began at
FHCSD PT Department in September 2017, an additional
group of PTF patients was added to evaluate functionality
improvements with early PT without prior opioid use and
redefined functionality based on ODI as the new primary
objective.17
Patients were included if they were 18 years or older,
completed 6 PT visits, diagnosed with CLBP for 3
months, and used either opioids or PT as first-line therapy
at the beginning of the study. Concomitant, nonopioid
pharmacologic and nonpharmacologic therapy was al-
lowed. Patients were excluded if they concomitantly used
opioids and physical therapy at the beginning of the
study.
Variables collected included demographics, comorbidities
(eg depression, musculoskeletal disorders, history of falls),
and opioid use based on the statewide prescription drug
monitoring program. Medications used were recorded at
the initial PT evaluation and post PT treatment. Using the 1
to 10 numeric pain rating scale, pain scores at the initial PT
evaluation and the last PToffice visit were collected. Patient
functionality was also collected at the initial PT evaluation
and at the last PT visit using a validated, self-administered
survey known as the ODI survey. This survey evaluates the
patient’s level of disability and assigns them to 1 of the 5
following categories: 0% to 20% minimal, 21% to 40%
moderate, 41% to 60% severe, 61% to 80% crippled, and
81% to 100% immobile.17 Changes in ODI scores greater
than 10% are considered clinically significant.17
The primary study outcome was functionality measured
by a reduction in ODI scores among CLBP patients only
using PT first. The secondary study outcomes compared
CLBP patients using either PT first versus opioid
treatment first. These outcomes were reduction in opioid
burden, as evidence by decreased opioid and nonopioid
medication use post-PT treatment, reduction in objective
pain scores post-PT, number of patients failing PT and
continuing or initiating opioids during study, and number
of patients lost to follow up.
Descriptive statistics evaluated demographics and base-
line characteristics. Wilcoxon signed rank reported a
change in ODI. Continuous variables were expressed as
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a mean 6 SD. Categorical variables were analyzed using
Fisher’s exact test. A P value ,.05 was considered
statistically significant for all outcomes, and a power level
of 0.9 was calculated to detect a 1-point difference in the
primary outcome for sample size. A multivariable logistic
regression was used to determine associations between
baseline medication use and change in functionality.
Corresponding 95% CI was calculated using a significance
level of 5% for logistic regression. Statistical analysis was
performed using IBM SPSSW, version 23 (Armonk, NY).
Results
Of the 316 eligible patients, 180 (57%) met inclusion
criteria (Figure). A total of 60 patients (33.3%) used
opioids as a first-line therapy, 60 (33.3%) used PT as a first-
line therapy, and 60 (33.3%) used PT first-line and
reported ODI scores. The FHSCD Department of PT began
using ODI for functionality in September 2017 and,
therefore, only 60 of the 120 PTF group had documented
ODI scores. In this study, most patients with CLBP
included were female, who were predominately Hispanic
followed by white (non-Hispanic) then black. More
patients in the OF group compared to both PTF groups
had a history of depression 53% versus 30.8% (P¼.11),
substance use disorder 30% versus 20% (P , .001), a fall
within the past year 45% versus 15.8% (P , .001), and on
average had more falls 1.1 6 1.6 versus 0.3 6 0.6
(P , .001; Table 1).
The PTF group showed improved functionality with a
mean ODI decrease of 11.9% (P , .001), with 61.7% having
an ODI reduction greater than 10% (Table 2). Subjective
pain scores decreased similarly among all groups and were
not statistically different between groups (Table 2). A
higher portion of patients in the OF group were lost to
follow up (68.3%) compared with the PTF group (38.3%;
P¼.026). Only 3.3% of patients in the PTF group failed PT
and required opioids versus 60% of patients in the OF
group, who failed PT and continued to require opioids
(P , .001; Table 2). Both opioid and nonopioid medications
decreased among each group (Table 2). The most common
opioids used at baseline were hydrocodone-acetamino-
phen (n¼ 34) followed by tramadol (n¼ 37; Table 2). The
most common nonopioid medications used at baseline
were nonsteroidal anti-inflammatory drugs (NSAIDs;
n¼ 115), acetaminophen (n¼ 67), and muscle relaxants
(n¼ 59). Total number of opioids used in the OF group
decreased by 48.3%, while nonopioid medication use
decreased by 29.9% in the OF group and 42.8% in the PTF
FIGURE: Patient selection of the chronic lower back pain (CLBP) study conducted at Family Health Centers of San Diego
(FHCSD; ODI ¼ Oswestry Disability Index; PT ¼ physical therapy)
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group (Table 2). Gabapentin was used by more OF patients
at baseline (n¼24 vs n¼9, P , .001) and was the only
non-opioid medication that showed increased use be-
tween both groups at PT completion. Multivariable logistic
regression showed baseline NSAIDs (P¼.004; CI 2.3-94.6;
odds ratio 14.8) and acetaminophen use (P¼.005; CI 2.1-
64.8; odds ratio 11.72) was associated with a greater than
10% change in ODI when controlled for chest pain, sex,
and initial ODI score.
Discussion
To our knowledge, this is the first assessment of early PT
intervention for pain, functionality, and opioid use in the
management of CLBP. Our results suggest early PT
significantly improves functionality of patients with CLBP.
Functional improvements included areas assessed in the
ODI: pain intensity, personal care, lifting, walking, sitting,
standing, sleeping, sex life, social life, and traveling.
Improvements in these areas are also areas targeted in
improving various psychiatric comorbidities such as
depression. Results showed early PT in CLBP provided
similar reductions in pain compared to patients using
opioids with PT. These findings are consistent with one
large, systematic review16 showing no benefit in chronic
pain control between opioids versus alternative nonopioid
medications. Krebs et al18 demonstrated similar reduction
in pain between opioids and nonopioid medications, but
nonopioids provided sustained reductions in pain relief as
opposed to opioids. These results also support CDC
recommendations to use nonpharmacologic and non-
opioid medications as first-line treatments for chronic
pain. Although no significant difference between groups
emerged in pain reduction, the positive trend suggests PT
with nonopioids provided comparable pain relief to PT
with opioids.
Fritz et al19 found an increased risk of long-term opioid
use with primary care versus physical therapy visits
following a new consultation for lower back pain.
Although infrequently used, PT incorporates nonpharma-
cologic pain management strategies including exercises,
spinal manipulation, and education to improve CLBP.19-21
Several studies19,22,23 suggest early use of PT are
associated with lower CLBP-related costs and reduced
use of MRI, spinal injections, and opioid use. While this
study did not focuse on the CLBP-related costs and use of
other services, PT did reduce the use of nonopioid and
opioid medications. Interestingly, most patients in the OF
group who failed PT and continued opioid medications still
received a benefit in pain reduction and decreased
number of medications used for pain relief. Therefore,
patients currently using opioids for CLBP may still benefit
from PT. Increasing PT referral and use may improve pain
and function in CLBP in addition to mitigating opioid use
to reduce overdose potential.19,22,24,25
TABLE 1: Patient demographics of the presented studya
Patient Characteristic OF Group (n ¼ 60) PTF Group (n ¼ 60) PTF þ ODI (n ¼ 60) P Valueb
Average age, mean 6 SD 53.4 6 12.2 46.1 6 14.9 43.3 6 14.1 .0041
Sex
Female, No. 41 34 38 .419
Race
White (non-Hispanic) 15 (25) 13 (22) 17 (28) NS
Hispanic 20 (33) 31 (52) 28 (47) NS
Asian 3 (5) 3 (5) 2 (3) NS
Black 16 (27) 11 (18) 10 (17) NS
Other 6 (10) 2 (3) 3 (5) NS
Depression 32 (53) 17 (28) 20 (33) .11
Anxiety 15 (25) 7 (12) 14 (23) .131
Substance use disorder history 18 (30) 20 (33) 4 (7) ,.001
Other mental health disorders 18 (30) 10 (17) 11 (18) .157
History of falls 27 (45) 8 (13) 11 (18) ,.001
Average No. of falls, mean 6 SDc 1.1 6 1.6 0.2 6 0.5 0.3 6 0.6 ,.001
Musculoskeletal disorders 46 (77) 37 (62) 13 (22) ,.001
NS¼ not significant; ODI¼ Oswestry Disability Index; OF ¼ opioids first group; PTF¼ physical therapy first group.
aUnless otherwise noted, data presented in No. (%) format.
bP values for demographics compares OF group to total of PTF and PTFþODI group.
cFalls averaged over total number of falls for the specified group.
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Our study also highlighted patients in the opioid group
had more comorbidities compared with PT group
including depression and patient falls. Depression is a
common comorbidity in patients with CLBP, which is
associated with higher opioid use and rates of substance
use disorder.19,26-30 Studies have shown individuals with
CLBP and psychological conditions do not respond to
opioid treatment and have an increased risk of long-term
use or misuse.19,31 Our results suggest that patients with
CLBP complicated by depression are more likely to be
prescribed opioids and have a higher risk for substance
use. It should be noted that depression rates with this
group may have led to high failure rates and increased
loss to follow up compared to PTF group.
Lastly, falls are also a common health concern contribut-
ing to patient morbidity and mortality in CLBP and opioid
use, especially in elderly (.65 years of age) who have a 4
to 5 times higher likelihood of falling while taking opioids
versus NSAIDs.32 In our study, a significantly higher
number of falls in patients taking opioids was seen, which
emphasizes the need for more cautious prescribing in
patients with CLBP as they are already limited in their
TABLE 2: Details of the study outcomesa
Primary Outcome PTF þ ODI
Functionality Scores Pre-PT Post-PT P Value
Mean 6 SD Oswestry score, % 39.8 6 19.8 27.9 6 26.3 ,.001
.10% change in Oswestry score, No. (%)b 37 (61.7) . . . . . .
Secondary Outcomes OF PTF PTF þ ODI P Valuec
Pain scores, mean 6 SDd
Pre-PT pain score 9.2 6 1.0 8.5 6 1.0 5.41 6 2.1 NS
Post-PT pain score 4.7 6 2.9 3.7 6 1.0 2 6 2.5 NS
PT completion, n
Failed PT and used opioids 36 3 1 .0001
Lost to follow up with PT 41 28 18 .026
OF PTF PTF þ ODI
Medication Usage, No. (%) Pre-PT Post-PT Pre-PT Post-PT Pre-PT Post-PT
Total opioids 91 (100) 47 (100) . . . 3 (100) . . . 1 (100)
Morphine 2 (2.2) 2 (4.3) . . . 1 (33.3) . . . 0
Codeine 8 (8.8) 0 . . . 0 . . . 0
Oxycodone 8 (8.8) 9 (19.1) . . . 1 (33.3) . . . 1 (100)
Hydrocodone 34 (37.4) 16 (34) . . . 0 . . . 0
Buprenorphine 2 (2.2) 0 . . . 0 . . . 0
Tramadol 37 (40.6) 20 (42.6) . . . 1 (33.3) . . . 0
Total nonopioids 127 (100) 93 (100) 85 (100) 36 (100) 67 (100) 54 (100)
NSAIDs 50 (39.4) 33 (35.5) 43 (50.6) 10 (27.8) 22 (32.8) 22 (40.7)
Acetaminophen 25 (19.7) 13 (13.9) 22 (25.9) 6 (16.7) 20 (29.9) 16 (29.6)
Muscle relaxant 23 (18.1) 18 (19.4) 14 (16.4) 8 (22.2) 22 (32.8) 10 (18.5)
Gabapentin 24 (18.9) 25 (26.9) 6 (7.1) 10 (27.8) 3 (4.5) 5 (9.3)
Unspecified 5 (3.9) 4 (4.3) 0 2 (5.5) 0 1 (1.9)
NS¼ not significant; NSAIDs¼ nonsteroidal anti-inflammatory drugs; ODI¼Oswestry Disability Index; OF¼ opioids first group; PT¼physical therapy;
PTF¼ physical therapy first group.
aN¼60 for the following groups: PTFþODI, OF, PTF, and PTFþODI.
bP value for mean Oswestry score compares only PTFþODI group prior to and after PT completion. A greater than 10% change in ODI indicates a
significant difference within 90% confidence interval.
cP values for PT completion outcomes compares OF group to total of PTF and PTFþODI group.
dPain score based on numeric scale from 1 to 10. Pain scores compared between all 3 groups without significance.
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mobility due to pain. The decision to prescribe opioids in
elderly with CLBP should be avoided if possible.
We acknowledge the limitations of this study as it was a
retrospective, single-center study with a majority female
population and may not be generalizable to all CLBP
populations. In contrast, retrospective design may be
reflective of clinical practice and prescribing patterns of
primary care setting in patients with CLBP. Additionally,
baseline characteristics in the OF group included older
patients with more musculoskeletal disorders, falls, and
mental health disorders representing a sicker group, which
may be prone to worse outcomes. Medication usage was
based on availability of information provided by the
electronic medical record, which limited our ability to
determine when medications were initiated or discontin-
ued as well as quantities and doses prescribed outside of
FHCSD. Moreover, we were unable to assess the use of
illicit substances, nonprescription opioids, or additional
nonpharmacologic treatments. Groups were not matched
and, thus, may include additional unidentified confound-
ers. Overall, the population size is small, and additional
patients would add to the robustness of these results. It
should be noted that ODI is a patient-assessed survey and
may exhibit response bias based on patient willingness to
report accurately. Only the total ODI score was available,
and assessment of the individual components from the
survey were not possible. The ODI scale was also
implemented in September 2017, leading to the low
number of patients included in this group as well as this
scale is not used in the OF group. Lastly, numeric pain
scores were not consistently monitored for trends among
patients in all groups.
Conclusion
Initial CLBP treatment with early PT leads to a significant
improvement in functionality, reduced pain scores, and
reduced medication burden for both treatment groups.The
OF treatment revealed no difference in pain reduction
compared to PT first, but this outcome was not evaluated
in functional improvement. Although PT improves func-
tionality, it is uncertain if PT is functionally beneficial
compared to opioids as this was not compared. These
findings suggest that PT interventions should be consid-
ered a first-line, nonpharmacologic treatment option for
CLBP along with nonopioid pharmacologic agents. Multiple
risks and limited efficacy restrict our ability to recommend
opioids as a safe, initial treatment option for CLBP.
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